Current developments in the treatment of cervical cancer

CME Journal of Gynecologic Oncology

Volumn 6, Issue 1, 2001, Pages 52-60

  Vermorken, J B ^a   Eisenhauer, E A ^a  

^a ANTWERP UNIVERSITY HOSPITAL   (Belgium)

Author keywords

Cervical cancer; Chemoradiation; Chemotherapy; Hyperthermia; Radiation therapy; Tumor oxygenation

Indexed keywords

BLEOMYCIN; CHLORAMBUCIL; CISPLATIN; CYTOTOXIC AGENT; DOCETAXEL; EPIRUBICIN; FLUOROURACIL; GEMCITABINE; HEMOGLOBIN; HYDROXYUREA; IFOSFAMIDE; IRINOTECAN; MELPHALAN; METHOTREXATE; MITOLACTOL; MITOMYCIN C; NAVELBINE; PACLITAXEL; PIRARUBICIN; PORFIROMYCIN; RADIOSENSITIZING AGENT; TOPOTECAN; VINBLASTINE; VINCRISTINE; VINDESINE;

ADJUVANT CHEMOTHERAPY; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURGERY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; HEMOGLOBIN DETERMINATION; HIGH RISK PATIENT; HUMAN; HYPERTHERMIC THERAPY; META ANALYSIS; MULTIMODALITY CANCER THERAPY; OXYGENATION; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; REVIEW; UTERINE CERVIX CANCER;

EID: 0034910640     PISSN: 12199087     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (122)

1. Estimates of the worldwide incidence of eighteen major cancers in 1985
2. A prospective surgical pathological study of stage I squamous carcinoma of the cervix
3. A review of prognostic factors in early stage carcinoma of the cervix (FIGO IB and IIA) and implications for treatment strategy
4. Pretreatment serum squamous cell carcinoma antigen: A newly identified prognostic factor in early-stage cervical carcinoma
5. Adenocarcinoma of the uterine cervix. Prognosis and patterns of failure in 367 cases
6. Pretreatment prognostic factors in carcinoma of the uterine cervix: A multivariate analysis of the effects of age, stage, histology and blood counts on survival
7. Prognostic value of hemoglobin concentrations and blood transfusions in advanced carcinoma of cervix treated by radiation therapy: Results of a retrospective study of 386 patients
8. Randomised study of radical surgery versus radiotherapy for stages IB-IIA cervical cancer
9. Adjuvant hysterectomy after radiation therapy reduces detection of local recurrence in "Bulky" stage IB cervical cancer without improving survival: Results of a prospective randomized GOG trial
10. Current developments in the treatment of newly diagnosed cervical cancer
11. The influence of treatment time on outcome for squamous cell cancer of the uterine cervix treated with radiation: A patterns-of-care study
12. The effect of treatment duration in the local control of cervix cancer
13. Overall treatment time in advanced cervical carcinomas: A critical parameter in treatment outcome
14. Carcinoma of the uterine cervix. I. Impact of prolongation of overall treatment time and timing of brachytherapy outcome of radiation therapy
15. The adverse effect of treatment prolongation in cervical carcinoma
16. Pretreatment and treatment factors associated with improved outcome in squamous cell carcinoma of the uterine cervix: A final report of the 1973 and 1978 patterns of care studies
17. The relationship between brachytherapy dose and outcome in patients with bulky endocervical tumors treated with radiation alone
18. Palliative chemotherapy for patients with cervical cancer. What is standard?
19. Chemotherapy for cervical carcinoma: Factors determining response and implications for clinical trial design
20. Chemotherapy as a palliative treatment in carcinoma of the uterine cervix
21. The role of chemotherapy in squamous cell carcinoma of the uterine cervix: A review
22. Randomized trial of three cisplatin dose schedules in squmaous cell carcinoma of the cervix: A Gynecologic Oncology Group Study
23. Phase II trial of high-dose cisplatin with sodium thiosulfate nephroprotection in patients with advanced carcinoma of the uterine cervix previously untreated with chemotherapy
24. Phase II randomized trial of cisplatin chemotherapy regimens in the treatment of recurrent or metastatic squamous cell cancer of the cervix: A Southwest Oncology Group Study
25. Cisplatin-based combination chemotherapy (BEMP) versus single agent cisplatin (P) in disseminated squamous cell carcinoma of the uterine cervix (SCCUC): Mature data of EORTC protocol 55863
26. Randomized trial of cisplatin versus cisplatin plus mitolactol (Dibromodulcitol) versus cisplatin plus ifosfamide in advanced squamous carcinoma of the cervix: A Gynecologic Oncology Group Study
27. Single agent versus combination chemotherapy in recurrent cervical cancer
28. A short and intensive single-agent cisplatin regimen for recurrent carcinoma of the uterine cervix
29. Hyperthermia and chemotherapeutic agents
30. The cytotoxic effect of CDDP on cultured CHO cells at elevated temperature: Arrhenius plot analysis
31. Response of peritoneal solid tumours after intraperitoneal chemohyperthermia treatment with cisplatin or carboplatin
32. A phase I/II study of combined weekly systemic cisplatin and locoregional hyperthemia in patients with previously irradiated recurrent carcinoma of the uterine cervix
33. Feasibility, toxicity and preliminary results of weekly locoregional hyperthermia and cisplatin in patients with previously irradiated recurrent cervical carcinoma or locally advanced bladder cancer
34. Weekly locoregional hyperthermia and cisplatin in patients with recurrent cervical cancer
35. Report of long-term follow-up in a randomized trial comparing radiation therapy and radiation plus hyperthermia to metastatic lymph nodes in stage IV head and neck patients
36. Randomised trial of hyperthermia as adjuvant to radiotherapy for recurrent or metastatic malignant melanoma
37. Radiotherapy with or without hyperthermia in the treatment of superficial localized breast cancer: Results from five randomized controlled trials
38. Survival benefit of hyperthermia in a prospective randomized trial of brachytherapy boost +/- hyperthermia for glioblastoma multiforme
39. Comparison of radiotherapy alone with radiotherapy plus hyperthermia in locally advanced pelvic tumours: A prospective, randomised, multicentre trial
40. Paclitaxel has moderate activity in squamous cervix cancer: A Gynecologic Oncology Group study
41. An update of a phase II study of paclitaxel in advanced or recurrent squamous cell cancer of the cervix
42. Preliminary report of the activity of docetaxel in advanced or recurrent squamous cell cancer of the cervix
43. Late phase II study of CPT-11, a topoisomerase I inhibitor, in advanced cervical carcinoma
44. Phase II study of irinotecan in prior chemotherapy-treated squamous cell carcinoma of the cervix
45. A phase II trial of CPT-11 in recurrent squamous carcinoma of the cervix: A Gynecologic Oncology Group study
46. A phase II study of irinotecan (CPT-11) in patients with advanced squamous cell carcinoma of the cervix
47. Results of a European Organization for Research and Treatment of Cancer/Early Clinical Studies Group phase II trial of first-line irinotecan in patients with advanced or recurrent squamous cell carcinoma of the cervix
48. Phase II trial of topotecan for cervical cancer of the uterus
49. Phase II study of pirarubicin (THP) in patients with cervical, endometrial and ovarian cancer: Study of the Clinical Screening Group of the European Organization for Research and Treatment of Cancer (EORTC)
50. Phase II study of vinorelbine in advanced and recurrent squamous cell carcinoma of the cervix
51. Vinorelbine as neoadjuvant chemotherapy in advanced cervical carcinoma
52. Phase II trial of vinorelbine in patients with advanced and/or recurrent cervical carcinoma: An EORTC Gynaecological Cancer Cooperative Group Study
53. A phase II study of gemcitabine in advanced cervix carcinoma: Final data
54. Evaluation of gemcitabine in patients with squamous cell carcinoma of the cervix: A phase II study of the Gynecologic Oncology Group
55. Combined modality treatment for carcinomas of the uterine cervix and vulva
56. Exploitable mechanisms in combined radiotherapy-chemotherapy: The concept of additivity
57. Combined modality therapy in cervical cancer
58. Long-term results of sequential chemotherapy-radiotherapy-chemotherapy in locally advanced squamous cell carcinoma of the uterine cervix
59. Chimiothérapie néoadjuvante des cancers du col utérin aux stades IIb et III. Résultats éloignés d'un essai randomisé pluricentrique portant sur 151 patients
60. Chemotherapy followed by radiotherapy versus radiotherapy alone in locally advanced cervical cancer. A randomized study
61. Neoadjuvant chemotherapy in locally advanced cervical cancer: Two randomised studies
62. A randomized trial of chemotherapy followed by pelvic radiation therapy in stage IIIB carcinoma of the cervix
63. A randomized trial comparing platinum-based chemotherapy followed by radiotherapy vs radiotherapy alone in patients with locally advanced cervical cancer
64. Randomized trial of epirubicin and cisplatin chemotherapy followed by pelvic radiation in locally advanced cervical cancer
65. The hazard of accelerated tumor clonogen repopulation during radiotherapy
66. Keynote address: Mechanisms of cross-resistance between radiation and antineoplastic drugs
67. High-dose cisplatin and bleomycin neoadjuvant chemotherapy plus radical surgery in locally advanced cervical carcinoma: A preliminary report
68. Neoadjuvant chemotherapy and radical surgery in locally advanced cervical cancer. Prognostic factors for response and survival
69. Induction chemotherapy followed by radical surgery in cervical cancer
70. A preoperative single course of high-dose cisplatin and bleomycin with glutathione protection in bulky stage IB/II carcinoma of the cervix
71. Neoadjuvant chemotherapy with vincristine and cisplatin followed by radical hysterectomy and pelvic lymphadenectomy for FIGO stage IB bulky cervical cancer: A Gynecologic Oncology Group pilot study
72. Neoadjuvant chemotherapy with cisplatin, ifosfamide and paclitaxel for locally advanced squamous-cell cervical cancer
73. Radical surgery after neoadjuvant intra-arterial chemotherapy in stage IIIb squamous cell carcinoma of the cervix
74. Long-term follow-up of neoadjuvant cisplatin and 5-fluorouracil chemotherapy in bulky squamous cell carcinoma of the cervix
75. Radical surgery following neoadjuvant chemotherapy for patients with stage IIIB cervical cancer
76. Wertheim's hysterectomy after neoadjuvant carboplatin-based chemotherapy in patients with cervical cancer stage IIB and IIIB
77. Long term follow-up of the first randomized trial using neoadjuvant chemotherapy in stage IB squamous carcinoma of the cervix: The final results
78. Randomized trial with neoadjuvant chemotherapy in stage IIIB squamous carcinoma cervix uteri: An unexpected therapeutic management
79. Randomized trial of neoadjuvant chemotherapy (NACT) followed by radical surgery (RS) vs exclusive radiotherapy (RT) in locally advanced squamosu cell cervical cancer (LASCCC). An Italian multicenter study
80. Neoadjuvant chemotherapy in cervical carcinoma stage IIB: A randomized controlled trial
81. Randomized trial of neoadjuvant cisplatin, vincristine, bleomycin, and radical hysterectomy versus radiation therapy for bulky stage IB and IIA cervical cancer
82. Hydroxyurea or placebo combined with radiation to treat stages IIIB and IV cervical cancer confined to the pelvis
83. Hydroxyurea: A radiation potentiater in carcinoma of the uterine cervix. A randomized double-blind study
84. A randomized trial of hydroxyurea versus misonidazole adjunct to radiation therapy in carcinoma of the cervix: A preliminary report of a Gynecologic Oncology Group Study
85. Long-term follow-up of potentiation of radiotherapy by cis-platinum in advanced cervical cancer
86. Cisplatin (CDDP) plus radiotherapy (RT) vs radiotherapy alone in locally advanced cervical cancer
87. Randomized study comparing chemotherapy plus radiotherapy versus radiotherapy alone in FIGO stage IIB-III cervical carcinoma
88. Induction chemotherapy and irradiation in advanced carcinoma of the cervix
89. A randomized trial of standard versus partially hyperfractionated radiation with or without concurrent 5-fluorouracil in locally advanced cervical cancer
90. A randomized comparison of fluorouracil plus cisplatin versus hydroxyurea as an adjunct to radiation therapy in stages IIB-IVA carcinoma of the cervix with negative para-aortic lymph nodes
91. Concurrent chemotherapy and pelvic radiation therapy compared with pelvic radiation therapy alone as adjuvant therapy after radical surgery in high-risk early-stage cancer of the cervix
92. Concurrent chemotherapy and pelvic radiation therapy compared with pelvic radiation therapy alone as adjuvant therapy after radical surgery in high-risk early-stage cancer of the cervix
93. Concurrent cisplatin-based radiotherapy and chemotherapy for locally advanced cervical cancer
94. Cisplatin, radiation, and adjuvant hysterectomy compared with radiation and adjuvant hysterectomy for bulky stage IB cervical cancer
95. A clinical trial comparing concurrent cisplatin and radiation therapy versus radiation alone for locally advanced squamous cell carcinoma of the cervix carried out by the National Cancer Institute of Canada Clinical Trials Group
96. Radiochemotherapy of uterine cervix cancers. Recent data
97. Concurrent chemotherapy and radiation for locally advanced cervical cancer: The new standard of care
98. Adjuvant chemotherapy and radiation in patients with poor prognostic stage Ib/IIa cervical cancer
99. Adjuvant chemotherapy after radical hysterectomy for cervical carcinoma
100. A pilot study of adjuvant therapy in patients with cervical cancer at high risk of recurrence after radical hysterectomy and pelvic lymphadenectomy
101. Adjuvant chemotherapy in high-risk patients after Wertheim hysterectomy - 10 Year survivals
102. A randomized trial of adjuvant chemotherapy after radical hysterectomy in stage IB-IIA cervical cancer patients with pelvic lymph node metastases
103. Chemotherapy versus radiotherapy versus observation for high-risk cervical carcinoma after radical hysterectomy: A randomized, prospective, multicenter trial
104. The effect of anemia on the radiotherapy results of the uterine cervix cancer
105. Relevance of oxygen in radiation oncology. Mechanisms of action, correlation to low hemoglobin levels
106. Association of hemoglobin levels before and during radiotherapy with prognosis in uterine cervix cancer
107. The impact of blood hemoglobin content on the outcome of radiotherapy. The Freiburg experience
108. The influence of anemia on the results of radiotherapy in carcinoma of the cervix
109. The importance of hemoglobin levels during radiotherapy for carcinoma of the cervix
110. The significance of anemia in clinical radiation therapy
111. Hemoglobin level and anemia in radiation oncology: Prognostic impact and therapeutic implications
112. Association between tumor hypoxia and malignant progression in advanced cancer of the uterine cervix
113. The prognostic significance of hypoxia in cervical cancer: A radiobiological or tumor biological phenomenon?
114. Immunmodulatorische wirkung der bluttransfusion und eingluss auf infektionsrate und tumorrezidiv
115. Adverse effects of allogenic blood transfusion
116. Exposure of patients to immunodeficiency virus through the transfusion of blood products that test antibody-negative
117. The declining risk of posttransfusion hepatitis C virus infection
118. Erythropoietin increases hemoglobin in cancer patients during radiation therapy
119. Erythropoietin increases hemoglobin during radiation therapy for cervical cancer
120. Effect of subcutaneous recombinant human erythropoietin in cancer patients receiving radiotherapy: Final report of randomized, open-labelled, phase II trial
121. Cisplatin-associated anaemia: An erythropoietin deficiency syndrome